Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling

NCT04710056 — Available, Regeneron Pharmaceuticals
ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT04710056
StatusAvailable
Study typeExpanded access
SponsorRegeneron Pharmaceuticals (Industry)
ConditionsLipodystrophy, Generalized Lipodystrophy (GLD), Monogenic Obesity (MOB)
InterventionsREGN4461 (Drug)
Datesfirst posted 2021-01-14, last updated 2026-03-12

Related Papers Related Patents Related Grants Related Experts
All trials for Lipodystrophy All trials for Generalized Lipodystrophy (GLD) All trials of REGN4461

-Summary

Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.

Expand all sections  ·  Collapse all

+Detailed description

Expanded Access requests are only being considered in response to Individual Patient and Intermediate-Size Population EAP Investigational New Drug (IND) applications. Availability will depend on location.

+Arms and interventions

  • REGN4461 (Drug), also known as mibavademab: To be provided by Regeneron

+Eligibility

Sex: All

Key Inclusion: N/A

Key Exclusion: N/A